In this edition:
KEYNOTE-564: OS results
CheckMate 914: adjuvant nivolumab in localised RCC
CheckMate 67T: SC vs. IV nivolumab in clear cell RCC
EV-302: subgroup analyses
AMBASSADOR: adjuvant pembrolizumab in muscle-invasive urothelial carcinoma
Prognostic models for stage I seminoma
CONTACT-2: cabozantinib + atezolizumab in relapsed mCRPC
BRCAAway: abiraterone + olaparib in mCRPC with HRRm
GETUG-AFU 18: dose-escalated radiotherapy + ADT in high-risk prostate cancer
ACE: cognitive function with abiraterone acetate vs. enzalutamide
Please login below to download this issue (PDF)